Navigation Links
Global Infectious Vaccines Partnering Terms and Agreements 2010-2016: Latest Deal Trends, Players and Financials for the World's Leading Pharma Companies
Date:3/16/2016

DUBLIN, March 16, 2016 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/p3dnz6/global_infectious) has announced the addition of the "Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials" report to their offering.

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2010, including financial terms where available, including over 600 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials includes:

  • Trends in infectious vaccines dealmaking in the biopharma industry since 2010
  • Analysis of infectious vaccines deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 600 infectious vaccines deal records
  • Identify the most active infectious vaccine dealmakers since 2010
  • The leading infectious vaccines deals by value since 2010
  • Includes adjuvant deals and alliances since 2010

In Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific infectious therapy target

For more information visit http://www.researchandmarkets.com/research/p3dnz6/global_infectious

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

 


'/>"/>
SOURCE Research and Markets
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
4. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. TRACE Releases 2012 Global Enforcement Report
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... the U.S. Food and Drug Administration (FDA) has notified the ... to its Zhejiang, China manufacturing facility ... "The successful clearance of the Warning Letter related to our ... a measure of the progress we have made in our ...
(Date:6/11/2017)...  Eli Lilly and Company (NYSE: LLY ) ... of galcanezumab, an investigational treatment for the prevention of ... key secondary endpoints for galcanezumab compared to placebo at ... EVOLVE-2 and REGAIN) will be presented today at the ... Boston . "The detailed ...
(Date:6/9/2017)... Calif. , June 9, 2017 AirXpanders, ... company focused on the design, manufacture, sale and distribution ... market on the progress of its commercial roll-out in ... now available in more than one hundred (100) medical ... AeroForm offers a needle-free alternative for women ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... Continually at the forefront of ... Drops™ have received the Non-GMO Project Verified seal. All five flavors of the ... only third-party verification for non-GMO foods and products in North America. , Available ...
(Date:6/28/2017)... Pekin, IL (PRWEB) , ... June 28, 2017 , ... ... research shows that every 62 minutes, at least one person dies as a direct ... grows, a greater need exists for qualified treatment providers. The iaedp Foundation meets this ...
(Date:6/28/2017)... ... June 28, 2017 , ... Canadian Zeolite Corp. (the “Company”) ... year study conducted by the University of Saskatchewan in partnership with PotashCorp, Agrium ... brine-impacted groundwater. As a part of the study, batch adsorption experiments were conducted ...
(Date:6/27/2017)... Fla. (PRWEB) , ... June 27, 2017 , ... ... today announced the appointment of Mike Finnegan to the position of Executive Vice ... years of experience in healthcare technology, telehealth and medical device sales leadership. He ...
(Date:6/27/2017)... ... 27, 2017 , ... The Congressional Budget Office (CBO) projects that the Better ... Patient Protection and Affordable Care Act (ACA), would result in 22 million Americans losing ... law. , More than 20 million Americans have gained health insurance under the ACA, ...
Breaking Medicine News(10 mins):